19 results about "Parasympathetic nerve" patented technology

The invention provides a cardiac autonomic neurodynamics quantitative evaluation method based on a phase ordering signal averaging technology. The cardiac autonomic neurodynamics quantitative evaluation method comprises an ECG signal preprocessing step, a QRS wave detection and processing step, a phase ordering signal averaging step and an autonomic neurodynamics quantitative analysis step. According to the cardiac autonomic neurodynamics quantitative evaluation method based on the phase ordering signal averaging technology, on the basis of inhibiting aperiodic interference and improving index stability in a complex physiological environment, continuous analysis of cardiac sympathetic nerve activity and cardiac parasympathetic nerve activity is carried out; time-varying CSI and CPI indexes are extracted to realize quantification of cardiac autonomic neurodynamics, and a lightweight algorithm framework is designed to adapt to real-time monitoring requirements of portable equipment.

Disclosed herein are systems and methods for locating and identifying nerves innervating the wall of arteries such as the renal artery. The present invention identifies areas on vessel walls that are innervated with nerves; provides indication on whether energy is delivered accurately to a targeted nerve; and provides immediate post-procedural assessment of the effect of energy delivered to the nerve. The methods includes evaluating a change in physiological parameters after energy is delivered to an arterial wall; and determining the type of nerve that the energy was directed to (sympathetic or parasympathetic or none) based on the evaluated results. The system includes at least a device for delivering energy to the wall of blood vessel; sensors for detecting physiological signals from a subject; and indicators to display results obtained using said method. Also provided are catheters for performing the mapping and ablating functions.

The invention provides a fatigue assessment method and device based on cardiac autonomic neurodynamics and brain coupling analysis, and the method comprises the steps: extracting time-varying CPI and CSI features representing cardiac autonomic neurodynamics features through a PRSA technology, carrying out the coupling analysis through different frequency bands of CPI, CSI and EEG, and carrying out the comprehensive, accurate and objective assessment of fatigue. On the basis of overcoming the defects of strong subjectivity and poor real-time performance of a subjective scale, through second-level dynamic quantization of sympathetic nerve and parasympathetic nerve activity states and brain activity coupling states, the limitation of traditional pure dependence on EEG or ECG spectral analysis and a static IPFM model can be effectively solved; the comprehensive and objective evaluation precision of the fatigue severity under the complex physiological state is improved, and the dynamic real-time monitoring requirement of the fatigue state is met.

This application provides a method, device, electronic device, and computer-readable storage medium for detecting drowsiness. The method includes: acquiring user physiological data; the user physiological data includes human parasympathetic nerve activation parameters and body activity state parameters; determining whether the user is in an awake state based on the human parasympathetic nerve activation parameters and body activity state parameters; and, if the user is in an awake state, determining whether the user is in a drowsy state based on the human parasympathetic nerve activation parameters. Determining whether a user is in a drowsy state using human parasympathetic nerve activation parameters and body activity state parameters can improve the accuracy of drowsiness detection.

The application relates to a radiofrequency ablation system and a radiofrequency ablation clamp for renal sympathetic denervation, which comprises an upper jaw and a lower jaw that can be opened and closed relative to each other, the upper jaw is provided with upper jaw radiofrequency electrodes, the lower jaw is provided with lower jaw radiofrequency electrodes, the lower jaw comprises a lower jaw main body in an arc structure with an axis extending along a left-right direction, a lower electrode seat made of insulating material corresponding to each lower jaw radiofrequency electrode is movably arranged on the lower jaw main body in a circumferential direction, each lower jaw radiofrequency electrode is fixed on the corresponding lower electrode seat, the upper jaw radiofrequency electrodes are at least three, each upper jaw radiofrequency electrode is arranged in a left-right direction at intervals, the lower jaw radiofrequency electrodes are at least three, each lower jaw radiofrequency electrode is arranged in a left-right direction at intervals, and the radiofrequency ablation clamp further comprises an electrode seat driving mechanism for driving the circumferential movement of the corresponding upper electrode seat and lower electrode seat. The purpose of the application is to provide a radiofrequency ablation system capable of retaining part of parasympathetic nerves and a radiofrequency ablation clamp used in the radiofrequency ablation system.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

A neurological state of a subject is accurately evaluated, and an evaluation result suitable for the subject is provided. A pupil index calculation unit generates waveform data of a pupil area based on a moving image in which a pupil of the subject is captured with a distortion-corrected lens, and then calculates a pupil index. The neurological state estimation unit estimates a sympathetic neural age and a parasympathetic neural age, which are neurological states for each of the left and right pupils of the subject, based on the pupil index. A comment generation unit evaluates the neurological state of the subject from the estimated neurological state, and the improvement measure generation unit generates advice suitable for the subject based on the evaluation result. A display unit displays the evaluation result of the neurological state and the advice in a neurological state evaluation system.

The invention provides a construction method of a rat xerophthalmia model, which utilizes scopolamine hydrobromide and 1% atropine sulfate ophthalmic gel to jointly induce xerophthalmia so as to induce comprehensive symptoms of rat xerophthalmia. After scopolamine hydrobromide is subcutaneously injected into a rat and atropine ophthalmic gel is dropwise added to eyes of the rat, difference appears in tear secretion, tear film rupture time and cornea staining detection from the second week, the symptom stability can last for more than one month, and obvious difference also exists in pathological examination of an anatomical end point and a TUNEL test. Hypodermic injection of scopolamine hydrobromide can inhibit parsympathetic nerve excitation so as to inhibit gland secretion, so that lacrimal secretion is insufficient; and meanwhile, the atropine ophthalmic gel can inhibit parasympathetic nerves, so that the threshold value of tear secretion is increased, and the tear secretion is reduced. The xerophthalmia model has the advantages that the modeling time is short, the modeling process is not limited by environment temperature and humidity, and model animals after modeling have small individual differences and high symptom specificity.

The invention relates to a pressure regulation and control method, device and equipment based on heart rate variability and a storage medium, and belongs to the field of pressure regulation and control. The method comprises the steps that in a control task, the blood volume change of subcutaneous capillary vessels of an operator is detected, and pulse wave signals for isolating vagus nerve electrical stimulation signal interference are collected in real time; after the collected pulse wave signals are subjected to preprocessing including amplification and filtering, the pulse wave signals are converted into a frequency domain for heart rate variability analysis, and a real-time pressure index in a control task is evaluated; establishing a pressure baseline, judging a real-time pressure level, adjusting stimulation parameters according to the pressure level to electrically stimulate the neck vagus nerve, and adjusting sympathetic-parasympathetic nerve balance to reduce pressure. The optimal physiological state of an operator is dynamically maintained on the premise that a control task is not interrupted, and safety, stability and high efficiency of high-precision operation are guaranteed.

The present disclosure includes: an ultrasound generating unit for irradiating the parasympathetic nerve with ultrasound waves; and a control unit for controlling the operation of the ultrasound generating unit, wherein the control unit controls the ultrasound generating unit so that the ultrasound generating unit applies ultrasound energy to a body part corresponding to the parasympathetic nerve.

The invention provides a neural state evaluation system. The neural state of a subject can be accurately evaluated, and an evaluation result suitable for the subject can be provided. A pupil index calculation unit generates waveform data of a pupil area on the basis of a moving image in which a pupil of a subject is imaged by an undistorted lens, and then calculates a pupil index, and a nerve state estimation unit estimates a sympathetic nerve age and a parasympathetic nerve age, which are nerve states of the left and right pupils of the subject, on the basis of the pupil index. The evaluation unit evaluates the neural state of the subject on the basis of the estimated neural state, the improvement measure generation unit generates a suggestion suitable for the subject on the basis of the evaluation result, and the display unit displays the evaluation result of the neural state and the suggestion.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

A system including: one or more electrodes configured to be disposed at one or more target treatment sites within a blood vessel of a patient; and processing circuitry configured to: determine a first characteristic of a cardiac cycle based on cardiac, cardiovascular and / or and systemic vascular signals; determine, based at least in part on the first characteristic, one or more first stimulation parameters for a first stimulation signal; determine a second characteristic of the cardiac cycle determine, based at least in part on the second characteristic, one or more second stimulation parameters for a second stimulation signal; and cause the one or more electrodes to deliver one or more of: the first stimulation signal to one or more nerves of the patient to cause a parasympathetic stimulation of the heart; or the second stimulation signals to the one or more nerves to cause a sympathetic stimulation of the heart.

The multi-modal biofeedback allergy defense massage control method comprises the following steps: acquiring multi-modal data of a user in a massage process in real time, determining whether the user has an allergy symptom before massage, and when the user has the allergy symptom before massage, outputting the acquired multi-modal data at a first moment as first multi-modal data; when the user does not have allergy symptoms before massage, constructing an antagonistic allergy risk model based on sympathetic / parasympathetic nerve activity indexes; performing real-time risk assessment by the antagonistic allergy risk model based on the multi-modal data acquired in real time, and outputting the multi-modal data as second multi-modal data when the risk assessment result is that the user has an allergy symptom; constructing a massage control model, and adjusting massage parameters of the massage equipment based on the first multi-modal data or the second multi-modal data by adopting the massage control model; according to the invention, the massage parameters of the user who is allergic or allergic in the massage process can be adjusted, so that the allergy symptom is relieved.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

To evaluate a degree of motion sickness.SOLUTION: An acquisition part acquires an active index value showing a degree of the activity of the sympathetic nerve or parasympathetic nerve of a user, calculated from vital data of the user. An evaluation part evaluates a degree of motion sickness of the user based on a distribution degree relating to the time sequence of the activity index value.SELECTED DRAWING: Figure 1

A parasympathetic nerve activation agent includes a compound represented by Structural Formula (1).